On August 31, 2026, JPMorgan Chase & Co. sold 1.25 million shares of InSilico Medicine Cayman TopCo (03696) at an average of HKD 43.5738 per share, involving about HKD 54.69 million.
Prior to the disposal, JPMorgan Chase & Co.'s long position in InSilico Medicine Cayman TopCo was 35.27 million shares, representing 6.05%; following the disposal, the holding changed to 34.01 million shares, with the long position ratio falling to 5.83%.